Product image of Metformina + Sitagliptina Polpharma (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Polpharma

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Polpharma (Metformin Hydrochloride, Sitagliptin)

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Polpharma, is a biguanide and DPP‑4 inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used in combination with diet and exercise.

GNH India supplies Metformina + Sitagliptina Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under GMP conditions.

Manufacturer / TM Owner

Zaklady Farmaceutyczne Polpharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Polpharma is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose levels.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to other antidiabetic agents.
  • Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise measures to achieve target HbA1c.

How It Works

  • Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition increases endogenous incretin hormones (GLP‑1 and GIP), which enhance glucose‑dependent insulin secretion and suppress glucagon release, together producing better glycaemic control.

Side Effects

Metformina + Sitagliptina Polpharma may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild persistent headache.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Decreased appetite: reduced food intake.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic condition.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Hepatic dysfunction: elevated liver enzymes.
  • Skin reactions: rash or Stevens‑Johnson syndrome.
  • Renal impairment: worsening kidney function.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Renal function assessment: avoid or adjust dose in patients with impaired kidney function.
  • Hepatic disease evaluation: use cautiously in liver disease.
  • Cardiovascular status: monitor for heart failure symptoms.
  • Pregnancy and lactation: safety not established; weigh risks and benefits.
  • Concomitant medications: review for potential interactions.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Sitagliptina Polpharma can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Iodinated contrast agents: risk of acute renal failure; discontinue metformin before and after imaging.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.
  • Insulin or sulfonylureas: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Diuretics (loop or thiazide): may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • Cimetidine: can raise metformin plasma concentrations.
  • Alcohol: increases risk of lactic acidosis.
  • Beta‑blockers: may mask hypoglycaemia symptoms.

Frequently Asked Questions

Metformina + Sitagliptina Polpharma is prescribed to adults with type 2 diabetes mellitus to improve blood glucose control. It works as part of a comprehensive treatment plan that includes diet, exercise, and possibly other antidiabetic medications.

Metformin hydrochloride lowers hepatic glucose production and increases peripheral insulin sensitivity, which helps reduce fasting blood glucose levels. It does not stimulate insulin secretion, making it suitable for patients with residual beta‑cell function.

The appropriate dose is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina + Sitagliptina combines a biguanide with a DPP‑4 inhibitor, offering complementary mechanisms: reduced hepatic glucose output and enhanced incretin‑mediated insulin secretion. Compared with sulfonylureas, it carries a lower risk of hypoglycaemia, and unlike GLP‑1 receptor agonists, it is administered orally.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use after the expiry date printed on the label.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious adverse events include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycaemia, particularly when used with insulin or sulfonylureas. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT